Oxymorphone transdermal - Phosphagenics

Drug Profile

Oxymorphone transdermal - Phosphagenics

Alternative Names: Oxymorphone patch - Phosphagenics; Oxymorphone TPM® Patch; TPM®/oxymorphone

Latest Information Update: 28 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Phosphagenics
  • Developer Phosphagenics; tesa Labtec
  • Class Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Pain

Highest Development Phases

  • Phase I/II Pain

Most Recent Events

  • 22 Aug 2017 Phosphagenics and Terumo enter into development agreement for oxymorphone transdermal in Japan
  • 12 Dec 2016 Early research in Pain in Japan and USA (Transdermal)
  • 10 Nov 2016 Phosphagenics extends the term of licence option, granted to Terumo under April 2016 agreement for TPM®-based Oxycodone patch in Japan (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top